Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024141 (
systemic lupus erythematosus
)
44,322
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The chief dangers reported with some common drugs are reviewed. Hazards of antibiotic therapy include: the increasing incidence of sensitization to penicillin with occasional anaphylactic reactions; aplastic anemia with chloramphenicol, and the poor tolerance of infants for chloramphenicol; staphylococcal enterocolitis; unnecessary "prophylactic" use of antibiotics. Thiazide diuretics may precipitate potassium depletion, skin reactions, pancreatitis, blood dyscrasias, gout, diabetes mellitus and hepatic coma.
Reserpine
can increase gastric acidity, induce mental depression, and when used with digitalis lead to ventricular premature beats. Hydralazine may aggravate angina pectoris, cause tachycardia, and bring about a syndrome resembling
disseminated lupus erythematosus
. Guanethidine may result in loose stools, impotence, and postural hypotension. Hazards of phenothiazines include jaundice, parkinsonian states and tremors, convulsions, hypotension, and blood dyscrasias. The butanediols have numerous side effects including gastrointestinal, cutaneous and hypotensive reactions. Prolonged corticosteroid therapy introduces a new danger in surgical treatment. The progesterone-like drugs may induce masculinization of the female fetus.
...
PMID:Dangers in the use of some potent drugs. 1398 37
We examined 62 women with three or more recurrent adverse pregnancy outcomes where we excluded the other well known causes of this state. We detected
lupus
anticoagulant (LAC) in three (5%), with the use of set of coagulation tests: activated partial thromboplastin time (APTT), APTT ratio, kaolin clotting time ratio (KCT), APTT of the 50:50 mixture of the patients and control plasmas, APTT ratio of the 50:50 mixture, phospholipid correction test and heat stability test. We excluded connective tissue disorders. Therapy was started between 12th and 14th gestational week. Efficacy was monitored in intervals of 2-6 weeks with following tests: APTT ratio, KCT and plateled count. Patient A, with strong LAC activity and thrombocytophenia, reacted weakly to therapy with
Pronison
40 mg/day and Aspirin 80 mg/day. The activity of LAC was slightly diminished but was present all the time. Patient expressed hypertension and gestational diabetes mellitus. The outcome of pregnancy was adverse and placenta had typical pathological changes. Patient B, with moderate LAC activity, reacted quickly and completly on therapy with
Pronison
20-40 mg/day and Aspirin 80 mg/day. The course of pregnancy was regular. The outcome was successful and placenta had no pathological changes. Patient C, with mild LAC activity, was treated only with Aspirin 80 mg/day. LAC activity rapidly disappeared, the course of pregnancy was regular and outcome was successful. On the basis of the first results we concluded that applied set of tests was sensitive for LAC of different intensity and that dissapeparance of LAC activity with the use of therapy anticipates successful pregnancy outcome.
...
PMID:[Lupus anticoagulant in pregnancy--first experiences in detection and therapy]. 1797 56